Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101088 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00101088: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00101088 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00101088, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of temsirolimus when given with imatinib mesylate in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus with imatinib mesylate may kill more cancer cells
Interventions
- OTHER laboratory biomarker analysis
- DRUG imatinib mesylate
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00101088
The ClinicalTrials.gov registry entry for NCT00101088 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00101088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00101088 about?
NCT00101088 is a clinical study titled "Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia". This phase I trial is studying the side effects and best dose of temsirolimus when given with imatinib mesylate in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of cancer cells, either by killing the c...
What is the current status of trial NCT00101088?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2005-04.
What interventions are being tested in trial NCT00101088?
The interventions under investigation include: laboratory biomarker analysis (OTHER), imatinib mesylate (DRUG), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00101088?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.